Clinical Trials Logo

Filter by:
NCT ID: NCT04859894 Recruiting - Covid19 Clinical Trials

Physiological Studies in Post-COVID-19 Syndrome, and the Association With DNA Methylation

Start date: April 20, 2021
Phase:
Study type: Observational

The physiological derangements in subjects suffering from long-term symptoms following a Covid-19 infection (Post-COVID-19 Syndrome) are poorly understood and evaluated. This study will recruit subjects with a clinical diagnosis of Post-Covid-19-syndrome) who are scheduled for either of lung function testing, cardiopulmonary exercise testing or cardiac ultrasound. Patients' symptoms will be correlated to physiological measures and compared to predicted values. In addition, in 20 patients, symptoms and physiological measures will be correlated to epigenetical alterations, or DNA-methylation patterns. In addition, a subset of patients will be examined a year after the baseline testing in order to follow the progress of the disease.

NCT ID: NCT04868214 Recruiting - Coagulation Clinical Trials

Multi-site Study for Evaluation of Clinical Ranges of Whole Blood Clotting Times of Patients on Anticoagulants and Verification of Measurement Precision of Liquid Quality Controls With the Perosphere Technologies' PoC Coagulometer

Start date: April 20, 2021
Phase:
Study type: Observational

The Perosphere Technologies' PoC Coagulometer measures clotting times of fresh whole blood samples. Clotting is initiated by glass surface activation and terminates on optical detection of fibrin assembly, the final step in the coagulation cascade. Since activation occurs at the top of the intrinsic pathway and detection occurs at the bottom of the final common pathway, the Perosphere Technologies' PoC Coagulometer has shown sensitivity to a broad range of drugs and reagents that affect blood clotting processes, including the Direct Oral Anticoagulants, DOACs (e.g. rivaroxaban, apixaban, and edoxaban), as well as the heparins (e.g. enoxaparin, a low molecular weight heparin, and unfractionated heparin). The purpose of the present study is to characterize the performance of the PoC Coagulometer measuring Clotting Time Controls, as well as fresh whole blood from both healthy volunteers and DOAC patients at three field testing sites.

NCT ID: NCT04868838 Recruiting - Lupus Nephritis Clinical Trials

Daratumumab to Treat Active Lupus Nephritis

Start date: April 20, 2021
Phase: Phase 2
Study type: Interventional

The purpose of this research is to study the safety and efficacy of daratumumab in inducing complete or partial remission in patients with active lupus nephritis.

NCT ID: NCT04869475 Recruiting - Clinical trials for Refractory Solid Tumors

Arsenic Trioxide in Refractory Solid Tumors With Rescuable p53 Mutation

Start date: April 20, 2021
Phase: Phase 2
Study type: Interventional

This study is an open, prospective, single arm, multi center exploratory basket clinical study. 20 refractory solid tumors patients with rescuable p53 mutation will be enrolled, and the efficacy and safety of arsenic trioxide in those patients will be evaluated.

NCT ID: NCT04872985 Recruiting - Breast Cancer Clinical Trials

Pyrotinib in Combination With Neoadjuvant Chemotherapy in HR+/HER2-, HER4 High Expression Breast Cancer Patients: A Phase II Trial

Start date: April 20, 2021
Phase: Phase 2
Study type: Interventional

This is a Phase II, single-center, double-blind, placebo-controlled, randomized study of Pyrotinib in combination with Doxorubicin/Epirubicin and Cyclophosphamide followed by Docetaxel/nab-Paclitaxel as neoadjuvant therapy for women with hormone receptor positive HER2-negative stage II to III breast cancer. Patients randomized to the study arm/control arm will receive standard neoadjuvant chemotherapy in combination with pyrotinib/placebo, respectively. The primary endpoint of the study is the total pathological complete response (pCR) rate. Secondary endpoints include the pCR rate in breast only, objective response rate(ORR), event-free survival, overall survival, and toxicity. We will also explore potential prognostic and predictive biomarkers.

NCT ID: NCT04888390 Recruiting - Heart Failure Clinical Trials

Exercise Intervention on Cardiorespiratory Function in HF With DM.

Start date: April 20, 2021
Phase: N/A
Study type: Interventional

Investigate the effects of exercise training on the cardiopulmonary function and exercise capacity in diabetes mellitus with heart failure.

NCT ID: NCT04898972 Recruiting - Clinical trials for Chronic Obstructive Pulmonary Disease

Mindfulness-based Intervention in COPD Dyads

MIND
Start date: April 20, 2021
Phase: N/A
Study type: Interventional

This study evaluates the effectiveness of a Mindfulness-Based Stress Reduction intervention (MBSRI) on the reduction of stress, anxiety, and depression in people with COPD and their family caregivers. The experimental group will receive the MBSRI and the control group an informational intervention on stress management.

NCT ID: NCT04903548 Recruiting - Clinical trials for Hepatocellular Carcinoma

Evaluating the Effects of Selective Treatment Utilizing Flex-dosing for Unresectable HCC With Y90 SIR-Spheres

Start date: April 20, 2021
Phase:
Study type: Observational

The overall objective of this research study is to evaluate outcomes associated with flex-dosing in Y90 SIR-Sphere administration in a prospective cohort of unresectable HCC patients eligible for segmental/super selective treatment at Methodist Dallas Medical Center (MDMC).

NCT ID: NCT04951362 Recruiting - Anosmia Clinical Trials

Role of Ivermectin Nanosuspension as Nasal Spray in Treatment of Persistant Post covid19 Anosmia

Start date: April 20, 2021
Phase: Phase 2/Phase 3
Study type: Interventional

ivermectin is FDA approaved antiparasitic drug which is also claimed to be having potent in vitro antiviral effect,so we are tryying to study itsovid19 anosmia effect upon releiving post covid19 anosmia

NCT ID: NCT04952935 Recruiting - Clinical trials for Congestive Heart Failure

Acupuncture for the Treatment of Medication-Dependent Hypotension in Heart Failure

Start date: April 20, 2021
Phase: Phase 1/Phase 2
Study type: Interventional

Acupuncture is believed to increase blood pressure in people who struggle with low blood pressure. This is a common problem facing people with heart failure, and sometimes these people need to take medications to artificially increase their blood pressure. This study is designed to determine if using acupuncture in people with heart failure can improve their blood pressure enough to not require medications to artificially increase blood pressure.